Business ❯Pharmaceuticals

Vertex Pharmaceuticals

Clinical Trials Shares

FDA Approves Vertex/CRISPR Gene Therapy for Beta Thalassemia

Casgevy, the first CRISPR-based treatment for TDT, to be available early this year at $2.2 million

Vertex's Non-Opioid Painkiller Shows Promising Results in Mid-Stage Trial